NAYA Biosciences, Inc. Common Stock (NAYA)

• Market cap: $1.02M
• 1 day: -10.36%
• 5 days: -21.36%
• 1 month: -52.08%
• 3 months: -82.27%
• 6 months: -80.25%
• Year to date: -82.84%
• 1 year: -82.61%
• 5 years: -99.76%
• 10 years: -99.76%
• Sector: Healthcare
• Industry: Medical Devices

About: NAYA Biosciences Inc is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health. Its portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a mode of action targeting non-responders to the current immunotherapy standard of care.

Employees: 30

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

2.45% less ownership

Funds ownership: 7.0% [Q3] → 4.55% (-2.45%) [Q4]

15% less capital invested

Capital invested by funds: $194K [Q3] → $165K (-$29.3K) [Q4]

25% less funds holding

Funds holding: 12 [Q3] → 9 (-3) [Q4]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $24 1,287% upside
• Avg. target: $24 1,287% upside
• High target: $24 1,287% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 15% 1-year accuracy 5 / 33 met price target

1,287% upside $24

Buy Upgraded

23 Jan 2025